Abstract
The invention in this patent application relates to chemical compounds represented herein generally by Formula 1a. These compounds are inhibitors of the Werner Syndrome ATP-dependent helicase (WRN) enzyme activity. The compounds of the invention may particularly be useful in treating cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair (dMMR) system.